Crossmark

Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application

Published Online: 2025-08-06

Published Print: 2025-10

Authors

Toliver, Joshua C.

Divino, Victoria

Ng, Carmen D.

Wang, Julia
Funding

Funding for this research was provided by:

This study was sponsored by Novo Nordisk Inc.
License Information

Text and Data Mining valid from 2025-08-06

Version of Record valid from 2025-08-06
More Information

Article History

Received: 26 June 2025

Accepted: 18 July 2025

First Online: 6 August 2025

Declarations

:

: Joshua C. Toliver, Victoria Divino, Carmen D. Ng, and Julia Wang are employees and shareholders of Novo Nordisk Inc.

: This study was performed in accordance with relevant guidelines and regulations, including the principles of the Helsinki Declaration of 1964 and its later amendments. This study used only secondary, de-identified data and did not involve the collection, use, or transmittal of individually identifiable data. WCG Institutional Review Board (Cary, NC, USA) granted a waiver exemption for this study from full institutional review board review. All patients enrolled in the WeGoTogether patient support program provided consent for their de-identified data to be used for research purposes.

Document is current